Metabolic disorders

Description

amyloidosis: A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.

Data source
FinnGen phenocode E4_METABOLIA
Include E4_AROMAMINO, E4_BRANCHAMINOFATAC, E4_AMINO, E4_LACTOSEINT, E4_CARBO, E4_SPHINGOLIP, E4_GLYCOSAMINOGLYC, E4_GLYCOPROT, E4_LIPOPROT, E4_PURINEPYRI, E4_PORBILIR, E4_MINERAL_MET, E4_CYSTFIBRO, E4_AMYLOIDOSIS, E4_VOLUME, E4_FLUIDELECTRO, E4_METABO
Level in the ICD-hierarchy 2
First defined in version DF2
Ontology
DOID 9120
GWAS catalog 1001875
MESH D000686
SNOMED CT 17602002

Key figures

Sex All Female Male
Number of individuals 12875 6472 6403
Unadjusted prevalence (%) 9.71 8.61 11.15
Mean age at first event (years) 61.61 62.15 61.07
Median number of events / individual 1 1 1

Clinical metrics

Sex All Female Male
Recurrence within 6 months (%) 22.94 23.07 22.8
Case fatality at 5-years (%) 9.08 8.24 9.93

Associations